
    
      The primary endpoint is objective response to everolimus after 6 months therapy (complete or
      partial response per ACTG criteria).

      Secondary endpoints are response according to physician global assessment, lesions size ,
      lesions infiltration, lymphedema, tolerance, pharmacodynamic (pathologic, angiogenic and
      lymphangiogenic biomarkers, HHV8 viral load sequential evaluation in the lesions,
      pharmacokinetic evaluation.
    
  